Literature DB >> 33803135

Efficacy of Surgery for the Treatment of Gastric Cancer Liver Metastases: A Systematic Review of the Literature and Meta-Analysis of Prognostic Factors.

Gianpaolo Marte1, Andrea Tufo1, Francesca Steccanella1, Ester Marra1, Piera Federico2, Angelica Petrillo2, Pietro Maida1.   

Abstract

BACKGROUND: In the last 10 years, the management of patients with gastric cancer liver metastases (GCLM) has changed from chemotherapy alone, towards a multidisciplinary treatment with liver surgery playing a leading role. The aim of this systematic review and meta-analysis is to assess the efficacy of hepatectomy for GCLM and to analyze the impact of related prognostic factors on long-term outcomes.
METHODS: The databases PubMed (Medline), EMBASE, and Google Scholar were searched for relevant articles from January 2010 to September 2020. We included prospective and retrospective studies that reported the outcomes after hepatectomy for GCLM. A systematic review of the literature and meta-analysis of prognostic factors was performed.
RESULTS: We included 40 studies, including 1573 participants who underwent hepatic resection for GCLM. Post-operative morbidity and 30-day mortality rates were 24.7% and 1.6%, respectively. One-year, 3-years, and 5-years overall survival (OS) were 72%, 37%, and 26%, respectively. The 1-year, 3-years, and 5-years disease-free survival (DFS) were 44%, 24%, and 22%, respectively. Well-moderately differentiated tumors, pT1-2 and pN0-1 adenocarcinoma, R0 resection, the presence of solitary metastasis, unilobar metastases, metachronous metastasis, and chemotherapy were all strongly positively associated to better OS and DFS.
CONCLUSION: In the present study, we demonstrated that hepatectomy for GCLM is feasible and provides benefits in terms of long-term survival. Identification of patient subgroups that could benefit from surgical treatment is mandatory in a multidisciplinary setting.

Entities:  

Keywords:  conversion surgery; gastric cancer; hepatectomy; liver metastasis; stage iv gastric cancer

Year:  2021        PMID: 33803135      PMCID: PMC7963158          DOI: 10.3390/jcm10051141

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  81 in total

Review 1.  Differences in gastric cancer surgery outcome between East and West: differences in surgery or different diseases?

Authors:  John Griniatsos; Dimitris Trafalis
Journal:  J BUON       Date:  2018 Sep-Oct       Impact factor: 2.533

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

4.  Surgical outcome of metachronous hepatic metastases secondary to gastric cancer.

Authors:  Sae Byeol Choi; Jyewon Song; Chang Moo Kang; Woo Jin Hyung; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Sung Hoon Noh; Choong Bai Kim
Journal:  Hepatogastroenterology       Date:  2010 Jan-Feb

Review 5.  Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience.

Authors:  L Ceniceros; A Chopitea; F Pardo; F Rotellar; L Arbea; J J Sola; J C Subtil; B Sangro; A Benito; J L Hernández-Lizoain; J Rodríguez
Journal:  Clin Transl Oncol       Date:  2017-10-17       Impact factor: 3.405

6.  Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer.

Authors:  Hironori Tsujimoto; Takashi Ichikura; Satoshi Ono; Hidekazu Sugasawa; Shuichi Hiraki; Naoko Sakamoto; Yoshihisa Yaguchi; Kazuo Hatsuse; Junji Yamamoto; Kazuo Hase
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

7.  Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?

Authors:  Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri; Fabrizio Romano
Journal:  HPB (Oxford)       Date:  2012-03       Impact factor: 3.647

8.  Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England.

Authors:  Sheraz R Markar; Hugh Mackenzie; Sameh Mikhail; Muntzer Mughal; Shaun R Preston; Nick D Maynard; Omar Faiz; George B Hanna
Journal:  Gastric Cancer       Date:  2016-03-03       Impact factor: 7.370

Review 9.  Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis.

Authors:  Sheraz R Markar; Sameh Mikhail; George Malietzis; Thanos Athanasiou; Christophe Mariette; Mitsuru Sasako; George B Hanna
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

10.  Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases.

Authors:  Yan-Na Wang; Kun-Tang Shen; Jia-Qian Ling; Xiao-Dong Gao; Ying-Yong Hou; Xue-Fei Wang; Jing Qin; Yi-Hong Sun; Xin-Yu Qin
Journal:  BMC Surg       Date:  2012-10-12       Impact factor: 2.102

View more
  2 in total

1.  Multimodality Treatment in Metastatic Gastric Cancer: Working Together to Tailor the Continuum of Care.

Authors:  Angelica Petrillo
Journal:  J Clin Med       Date:  2021-11-24       Impact factor: 4.241

2.  Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis.

Authors:  Dandan Yu; Jinru Yang; Min Jin; Bin Zhou; Linli Shi; Lei Zhao; Jieying Zhang; Zhenyu Lin; Jinghua Ren; Li Liu; Tao Zhang; Hongli Liu
Journal:  mBio       Date:  2021-12-07       Impact factor: 7.867

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.